Earnings Releases·Nov 13, 2026, 4:05 PM ET

Enveric Biosciences — Third Quarter 2026 Earnings Summary

Net loss narrowed to $2.5 million in Q3 2026 from $3.4 million in the prior year period, driven by a non-recurring $1.5 million deemed dividend in 2025; cash-on-hand stands at $5.6 million.
The Company is advancing final IND-enabling activities for lead candidate EB-003, with a planned IND submission followed by a first-in-human Phase 1 trial.
Positive preclinical data for EB-003 includes favorable absorption/metabolic studies, distinct brain activity patterns via qEEG, and in vitro evidence supporting a non-hallucinogenic profile.
The EVM401 series secured a U.S. patent allowance for next-generation non-hallucinogenic mescaline derivatives.
Management maintains an optimistic outlook regarding EB-003's potential for fast-acting antidepressant effects, though risks regarding funding, manufacturing scale-up, and going concern status remain.